Latuda®(lurasidone) tablets – retrospective reimbursement price adjustment for April 2024
Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has retrospectively adjusted the reimbursement prices for all strengths of Latuda® (lurasidone) tablets dispensed in April 2024.
On 1 April 2024, there was an increase in the NHS list prices of Latuda® (all strengths) manufactured by CNX Therapeutics Ltd. Under the current price change mechanism, the new list prices would only apply to reimbursement for NHS prescriptions dispensed from May 2024.
To avoid pharmacy owners dispensing these products at a loss, DHSC has granted the following reimbursement price changes for the dispensing month of April 2024. The retrospective price adjustments will apply to both branded and generically written prescriptions for lurasidone tablets.
| Generic name | Brand name | Pack size | Previous reimbursement price | Retrospectively adjusted reimbursement price (effective from April 2024) |
| Lurasidone 18.5mg tablets | Latuda® 18.5mg tablets | 28 | £37.60 | £80.00 |
| Lurasidone 37mg tablets | Latuda® 37mg tablets | 28 | £37.60 | £80.00 |
| Lurasidone 74mg tablets | Latuda® 74mg tablets | 28 | £37.60 | £80.00 |
For these products pricing adjustments are planned to be included in the June 2024 Schedule of Payments (with a payment dates of 30th August 2024). The payments will appear as ‘Adjustment drugs‘ and ‘Adjustment fees’ (if applicable). The adjustments for products listed above will be shown as a combined total.
